AP
TEVA icon

Antipodes Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Antipodes Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,234
Closed -$67.3K – 153
2026
Q1 		$67.3K Buy
2,234
+148
+7% +$4.76K ﹤0.01% 103
2025
Q4 		$65.1K Buy
+2,086
New +$51.4K ﹤0.01% 102

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Antipodes Partners's TEVA Position: Q2 2026 in Review

Antipodes Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 2,234 shares — an estimated $67.3K sold.

Antipodes Partners first reported a position in TEVA in Q4 2025 and held it in 2 quarters. The position peaked at $67.3K in Q1 2026. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Antipodes Partners reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Antipodes Partners sold 2,234 Teva Pharmaceuticals shares in Q2 2026, an estimated $67.3K.
  • Antipodes Partners first reported a position in Teva Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Antipodes Partners's Teva Pharmaceuticals position peaked at $67.3K in Q1 2026.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.